Provenienza dei contatti di primo grado di Isabella Attinger-Toller
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Isabella Attinger-Toller tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ALCON INC. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
RetroSense Therapeutics LLC
RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Medical Specialties | Director/Board Member | |
University of Oxford | College/University | Graduate Degree | |
Thommen Medical AG
Thommen Medical AG Medical SpecialtiesHealth Technology Thommen Medical AG develops and manufactures dental implant systems. It offers include implants, prosthetics, digital solutions, and case planning. The company Grenchen, Switzerland. | Medical Specialties | Director/Board Member | |
The University of California, San Francisco | College/University | Corporate Officer/Principal | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Founder | |
Technische Universität München | College/University | Graduate Degree | |
Moscow State University Lomonosov | College/University | Undergraduate Degree | |
University of Zurich | College/University | Doctorate Degree Undergraduate Degree | |
Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | Investment Managers | Private Equity Investor | |
University of Koblenz | College/University | Undergraduate Degree | |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Medical Specialties | Director/Board Member | |
Redalpine Venture Partners AG
Redalpine Venture Partners AG Investment ManagersFinance Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006. | Investment Managers | Founder | |
MEDMIRA INC. | Medical Specialties | Director/Board Member | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Founder | |
ACREDIS qmc AG
ACREDIS qmc AG Miscellaneous Commercial ServicesCommercial Services ACREDIS qmc AG engages in the provision of project and quality management, marketing, procurement, logistics, and distribution services for the healthcare, hotel, and restaurant service providers focusing on consumer and durable goods. It also acquires participating interests in firms, as well as acquires, manages, and sells licenses, patents, and other intangible assets. The company was founded by Stephan Hägeli on February 22, 2006 and is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Cell Medica Switzerland AG
Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Boston Consulting Group Holding AG
Boston Consulting Group Holding AG MiscellaneousMiscellaneous Part of The Boston Consulting Group, Inc., Boston Consulting Group Holding AG operates as a holding Swiss company. The company is based in Zurich, Switzerland. Founded in 1963. | Miscellaneous | Corporate Officer/Principal | |
BiognoSYS AG
BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
Redbiotec AG
Redbiotec AG Medical/Nursing ServicesHealth Services Redbiotec AG develops and produces multi protein assemblies. It specializes in producing virus-like particles, various types of protein complexes and single proteins and VLP-based vaccines against various infectious diseases. The firms products are used in complex drug target, structural studies, target validation, antibody generation, biopharmaceutical and VLP applications. The company was founded in 2006 by Christian Schaub and Corinne John and is headquartered in Schlieren, Switzerland. | Medical/Nursing Services | Director/Board Member | |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Swiss Biotech Association operates as an industry association. The private company is based in Zurich, Switzerland. Michael Altorfer has been the CEO of the Swiss company since 2018. | Miscellaneous Commercial Services | President | |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
MedMira Holding AG
MedMira Holding AG Medical/Nursing ServicesHealth Services MedMira Holding AG operates as a holding company with interests in developing and manufacturing medical diagnostics and technologies. The firm provides medical progress to customers from all over the world while combining the quality with economical sustainability. The company was founded on December 22, 2008 and is headquartered in Zug, Switzerland. | Medical/Nursing Services | Director/Board Member | |
Kellogg School of Management | College/University | Masters Business Admin | |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Pharmaceuticals: Other | Director/Board Member | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Lunaphore Technologies SA
Lunaphore Technologies SA BiotechnologyHealth Technology Lunaphore Technologies SA develops tissue diagnostics solutions. Its products include in vitro diagnostics, automated staining instruments, and consumables. The company was founded by Ata Tuna Ciftlik, Diego Gabriel Dupouy, and D?borah Heintze in April 2014 and is headquartered in Tolochenaz, Switzerland. | Biotechnology | Director/Board Member | |
KUROS BIOSCIENCES AG | Biotechnology | Director/Board Member | |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | Pharmaceuticals: Major | Director/Board Member | |
Inositec AG
Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Revolo Biotherapeutics Ltd.
Revolo Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member | |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Biotechnology | Founder | |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Hornet Therapeutics Ltd.
Hornet Therapeutics Ltd. BiotechnologyHealth Technology Hornet Therapeutics Ltd. provides immune cell metabolism and cell therapy for cancer treatment. The company is based in London, UK and was founded in 2019. | Biotechnology | Director/Board Member | |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member | |
Cardiola AG
Cardiola AG Medical SpecialtiesHealth Technology Cardiola AG develops solutions for treating congestive heart failure. It conducts research on treating heart failure. The firm manufactures therapeutic device for heart treatment services. The company was founded by Larryin Lapanashvili in 2000 and it is headquartered in Winterhur, Switzerland. | Medical Specialties | Director/Board Member |
Statistiche
Distribuzione geografica
Svizzera | 30 |
Stati Uniti | 8 |
Germania | 6 |
Regno Unito | 5 |
Russia | 2 |
Settori
Health Technology | 25 |
Consumer Services | 9 |
Commercial Services | 8 |
Finance | 5 |
Health Services | 4 |
Posizioni
Director/Board Member | 35 |
Corporate Officer/Principal | 10 |
Founder | 8 |
Private Equity Investor | 5 |
Chairman | 5 |
Contatti più connessi
Insiders | |
---|---|
Arnd Kaltofen-Ehmann | 16 |
Dominik Escher | 15 |
Michael Sidler | 13 |
Dmitry Kuzmin | 9 |
Dragan Grabulovski | 5 |
Philipp Spycher | 1 |
Martin Behe | 1 |
Roger Schibli | 1 |
- Borsa valori
- Insiders
- Isabella Attinger-Toller
- Connessioni Società